Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AVBP stock hub

ArriVent BioPharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AVBPis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.4B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AVBP

In the news

Latest news · AVBP

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-58.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-39.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AVBP market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

163

Groups with data

Currency

USD

Showing 163 of 163 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001868279
Company name	ArriVent BioPharma, Inc.
Country	United States
Country code	US
Cusip	04272N102
Employees	77
Employees Change	25%
Employees Change Percent	48.08
Enterprise value	$1.1B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2024-01-26
Isin	US04272N1028
Last refreshed	2026-05-10
Market cap	$1.4B
Market cap category	Small-Cap
Price	$29.48
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	AVBP
Website	https://arrivent.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.16%
P/B ratio	4.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-166.3M
Net Income Growth Years	0%
Profit Per Employee	$-2.2M
ROA	-36.49
ROCE	-57.79
ROE	-58.88
ROIC	-39.27

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	48.93%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$333.2M
Cash	$312.8M
Current Assets	$332.9M
Current Liabilities	$25.9M
Debt	$14,000
Debt Equity	$0
Equity	$307.2M
Liabilities	$25.9M
Long Term Assets	$272,000
Long Term Liabilities	$0
Net Cash	$312.8M
Net Cash By Market Cap	$22.87
Net Cash Growth	43.04%
Net Debt Equity	$-1.02
Tangible Book Value	$307.2M
Tangible Book Value Per Share	$7.24
WACC	12.62

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.83
Net Working Capital	$-5.9M
Quick ratio	12.06
Working Capital	$307M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-22.22%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	48.89%
200-day SMA	21.99
50-day SMA	26.26
50-day SMA vs 200-day SMA	50over200
All Time High	36.37
All Time High Change	-18.94%
All Time High Date	2024-11-08
All Time Low	14.35
All Time Low Change	105.44%
All Time Low Date	2024-04-25
ATR	1.65
Beta	1.52
Beta1y	0.62
Beta2y	1.12
Ch YTD	46.52
High	30.05
High52	32.14
High52 Date	2026-04-21
High52ch	-8.28%
Low	28.67
Low52	16.1
Low52 Date	2025-08-12
Low52ch	83.11%
Ma50ch	12.27%
Price vs 200-day SMA	34.04%
RSI	55.86
RSI Monthly	58.41
RSI Weekly	66.99
Sharpe ratio	0.92x
Sortino ratio	1.59
Total Return	-22.22%
Tr YTD	46.52
Tr1m	17.03%
Tr1w	-1.7%
Tr3m	34.86%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	12
Analyst Count Top	2
Analyst Price Target Top	$44.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.89
Operating Income	$-177.5M
Price target	$42.18
Price Target Change	$43.08
Price Target Change Top	$50.95

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	29,890,944%
Float Percent	64.46%
Shares Insiders	1.93%
Shares Institutions	60.32%
Shares Out	46,368,442
Shares Qo Q	2.46%
Shares Yo Y	22.22%
Short Float	25.65%
Short Ratio	15.9
Short Shares	16.53

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	447,091.2x
Bv Per Share	7.24
Ch1m	17.03
Ch1w	-1.7
Ch1y	48.89
Ch3m	34.86
Ch6m	63.37
Change	2.18%
Change From Open	1.97
Close	28.85
Days Gap	0.21
Dollar Volume	7,988,962.1
Earnings Date	2026-05-11
Earnings Time	bmo
EBIT	$-177.5M
EPS	$-4.32
F Score	1
Financing CF	203,063,000
Fiscal Year End	December
Founded	2,021
Investing CF	-71,228,000
Ipr	63.78
Iprfo	22.83
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-05
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-05
Ma150	22.98
Ma150ch	28.27%
Ma20	29.87
Ma20ch	-1.32%
Net CF	-28,753,000
Next Earnings Date	2026-05-22
Open	28.91
Optionable	Yes
Position In Range	58.7
Post Close	29.48
Postmarket Change Percent	0.07
Postmarket Price	$29.5
Ppne	13,000
Price Date	2026-05-08
Ptbv Ratio	4.45
Relative Volume	0.61x
Share Based Comp	12,520,000
Tr6m	63.37%
Us State	Pennsylvania
Volume	270,996

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AVBP pay a dividend?

Capital-return profile for this ticker.

Performance

AVBP stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AVBP?

Insider, institutional, and short-interest positioning.

Institutional ownership

+60.3%

Float: +64.5% of shares outstanding

Insider ownership

+1.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AVBP momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.9

Neutral momentum band

Price vs 200-day MA

+34.0%

50/200-day relationship not available

Beta (5Y)

1.52

More volatile than the market

Sharpe ratio

0.92

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AVBP

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AVBP stock rating?

ArriVent BioPharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AVBP analysis?

The full report lives at /stocks/AVBP/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AVBP?

The latest report frames AVBP around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AVBP page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.